NEWCASTLE UPON TYNE, UK, 01 APRIL 2022. QuantuMDx Group Limited (“QuantuMDx”), is pleased to announce that it has won two Bionow Awards 2021, which took place last night, Thursday 31 March 2022. The company was shortlisted for three awards, winning two in total.
- The scaling up of manufacturing of QuantuMDx’s Q-POC™ won Project of the Year, recognising the innovative approach QuantuMDx used to manufacture Q-POC™ at speed under intense circumstances
- Molly Jowsey, Senior Mechanical Engineer at QuantuMDx, won Promising Technologist of the Year
The company is particularly pleased to recognise Molly Jowsey, who won Promising Technologist of the Year award. Molly has worked at QuantuMDx for a number of years, most recently working on the development of its diagnostics cassette for SARS-CoV-2 and will play a central role in the development of the company’s future R&D projects, including a multiplex respiratory panel, which is due to be launched later this year.
Jonathan O’Halloran, Chief Executive, QuantuMDx, said: “These awards validate our innovative technology and hard-working team. Particular congratulations go to Molly Jowsey on receipt of her award for Promising Technologist of the Year, which demonstrates the incredible talent we have at QuantuMDx.”
“We are continuing to build on the momentum of the last year, during which we were pleased to receive CDTA approval of our Q-POC™ SARS-CoV-2 assay and the company is now working to expand the menu of tests for Q-POC™ including the addition of a multiplex respiratory panel, which we are aiming to launch later this year, and a panel for sexually transmitted infections.” testified Jonathan O’Halloran.
The Chief Executive of QuantuMDx said “We remain committed to providing accurate and affordable testing at the point of need and are looking forward to providing further updates on our innovative product range in due course.”
Notes for editor:
QuantuMDx is a progressive MedTech company passionate about empowering the world to control disease and reduce suffering. QuantuMDx solves real-world diagnostic problems by creating multiplex molecular solutions for the Point of Need, for anyone, anywhere.
QuantuMDx has global operations and strategic partnerships – keeping it at the forefront of molecular diagnostics.
Q-POC™ is a rapid, simple to use, portable, sample to answer PCR device and has been designed for use in a wide range of settings, such as hospitals, clinics, pharmacies, and workplace testing providing accurate PCR results at the Point of Need. Q-POC™ and its first test, a SARS-CoV-2 multiplex detection assay, are CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within Europe. It tests multiple targets of the disease for a future proof COVID-19 testing solution at the Point of Need.
QuantuMDx plans to launch a range of syndromic multiplex testing assays over the coming months and years.
For more information about QuantuMDx and Q-POC™, its rapid PCR point of care system, go to: www.quantumdx.local.
For media enquiries and interview requests:
Emma Long, Marketing Communications Manager, QuantuMDx,
M: +44 (0) 7495 341 930 T: +44 (0) 870 803 1234 / firstname.lastname@example.org
Chris Gardner, Matthew Neal and Lindsey Neville, Consilium Strategic Communications,
+44 (0)20 3709 5700 / email@example.com
For investor enquiries:
David Wilson, Nigel Barnes and Jeff Glushakow, WG Partners (Financial Adviser to QuantuMDx), +44 (0)20 3705 9330 / firstname.lastname@example.org